Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma
Authors:
- 1 March 1994
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 5 (3) , 233-237
Abstract
No effective salvage therapy is known for patients with metastatic colorectal carcinoma progressive after chemotherapy with 5-fluorouracil (5-FU)/folinic acid (FA) or 5-FU/alpha interferon (IFN) combinations. The aim of the study was to test whether weekly FA/high-dose 5-FU is an effective therapy in pretreated patients with progressive metastatic colorectal carcinoma. Between January and December 1992, 57 patients with metastatic colorectal carcinoma were treated with weekly infusions of high-dose 5-fluorouracil (5-FU) (2600 mg/m2 as 24-hour infusion) and folinic acid (FA) (500 mg/m2 as 1-hour infusion prior to 5-FU). All patients were pretreated with chemotherapy, most of them with regimens containing 5-FU i.v. bolus/FA or 5-FU/alfa interferon (IFN), and all had documented progressive disease at the time of entering the study. In patients with partial remission (PR) or stable disease (SD) with improvement of their clinical condition, therapy was continued until progressive disease (PD) was documented. In all other patients therapy was stopped after one course (6 infusions). 5/57 patients (9%) achieved PR, 32/57 (56%) SD, in 19/57 (33%) disease was progressive and one toxic death occured. 26/32 patients (81%) with SD or PR after the first chemotherapy again obtained SD or PR on high-dose 5-FU/FA but only 8/18 (44%) of those with PD after first chemotherapy did so. The median duration of SD/PR was 3 months and the median survival for all patients 8 months (range 3–17+). Apart from one toxic death, toxicity consisting for the most part of mucositis (n = 24), nausea (n = 23), diarrhoea (n – 18) and hand-foot syndrome (n = 12) was moderate. Pretreated patients with metastatic colorectal carcinoma, notably those with a primary PR or SD, can probably benefit from weekly high-dose 5-FU/FA.Keywords
This publication has 20 references indexed in Scilit:
- Recent advances in the treatment of advanced colorectal cancerCancer, 1993
- Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinomaEuropean Journal of Cancer, 1992
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1992
- A phase I–II study of 14-days continuous infusion of 5-fluorouracil with weekly bolus leucovorin in metastatic colorectal carcinomaEuropean Journal of Cancer, 1992
- Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma assessment of activity and toxicityCancer, 1990
- Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.Journal of Clinical Oncology, 1990
- Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancerEuropean Journal of Cancer, 1990
- Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancerCancer, 1989
- Reporting results of cancer treatmentCancer, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958